SAGA Diagnostics is a pioneering company focused on revolutionizing the early detection of Molecular Residual Disease (MRD) to personalize cancer treatment. Their unique MRD testing platform, based on proprietary hybrid technologies utilizing next-generation sequencing (NGS) and digital PCR, enables highly sensitive and specific detection of residual cancer following treatment. By leveraging tumor-specific structural variants to create a unique genetic fingerprint for each patient's cancer, SAGA Diagnostics provides oncologists, researchers, and drug developers with precise tools to monitor treatment response and detect disease early. Their liquid biopsy test is designed to continuously monitor a patient's cancer through simple blood draws, offering clarity and confidence at all stages of treatment. This innovative approach is helping improve cancer therapy decision-making and is a valuable partner for biopharma in accelerating drug development and commercialization efforts.
Cancer companion diagnostics β’ Circulating tumor DNA analysis β’ Tissue analysis β’ Actionable mutations β’ Mutation screening
22 hours ago
Vice President role focused on market access strategies for oncology diagnostics. Engage with stakeholders to ensure product access and reimbursement.
October 19
Drive biopharma partnerships for cancer diagnostics at SAGA Diagnostics.